Continue pushing until sickle cell disease grants are secured and the sickle cell community has the certainty it deserves.

I will not stop pushing until these grants are secured and the sickle cell community has the certainty it deserves.

Carter pledges to keep pressing until the sickle cell grant funding is finalized.

Representative Troy Carter |
primary · press_release · model gpt-5.4-mini

Carter's office said he and Rep. Alma Adams sent HHS/HRSA a letter urging HRSA not to delay Sickle Cell Disease Newborn Screening Follow-Up Program funding. The release states the current five-year grant cycle ends August 31, 2026, HRSA had not issued a new NOFO, and Carter said he would not stop pushing until the grants were secured.

This directly matches the promise and shows concrete advocacy, but also says the grants were not yet secured as of June 8, 2026.

unresolved same_term A for effort

Representative Troy Carter |
primary · model gpt-5.5 · confidence 94%

The FY 2026 HRSA operating plan lists Maternal and Child Health SPRANS - Sickle Cell at $7.000 million for FY 2025 and $7.000 million for FY 2026, and separately lists Sickle Cell Service Demonstrations at $8.205 million for FY 2026.

Official HRSA budget data supports Carter's statement that Congress provided FY 2026 funding, but budget authority alone does not prove that the follow-up grants or new grant cycle were awarded.

partial same_term A for effort

Health Resources and Services Administration Operating Plan for FY 2026
secondary · model gpt-5.5 · confidence 91%

HRSA says it funds a portfolio of three sickle cell programs. The Sickle Cell Disease Newborn Screening Follow-Up Program funds 25 community-based organizations that help families affected by sickle cell disease get local resources and care; the page links to an archived HRSA-21-036 funding notice.

This confirms the federal grant program and 25-CBO structure Carter was trying to protect, while the archived notice suggests the existing cycle predated the 2026 push for renewed certainty.

partial unknown

HRSA Maternal and Child Health Bureau - Sickle Cell Disease Programs
secondary · model gpt-5.5 · confidence 88%

HRSA lists community-based organizations leading follow-up programs in five regions, including Baton Rouge Sickle Cell Anemia Foundation, Inc. in Louisiana.

This verifies that the Follow-Up Program serves Louisiana and other regions through named community organizations, making the promised grants relevant to Carter's district/state interests. It does not show renewed grants were secured.

partial unknown

HRSA Maternal and Child Health Bureau - Sickle Cell Disease Program Partners
secondary · model gpt-5.5 · confidence 84%

The FY 2026 budget justification says the budget provides $8.2 million for regional sickle cell disease infrastructure and describes the Sickle Cell Disease Treatment Demonstration Program as a competitive grant/cooperative agreement program supporting comprehensive care teams.

This corroborates continued federal budget support for sickle-cell infrastructure, but it concerns the treatment demonstration program rather than proving the newborn screening follow-up grants were newly awarded.

partial same_term

FY 2026 Administration for a Healthy America Congressional Budget Justification
secondary · model gpt-5.5 · confidence 78%